Latest Share Chat

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Thu, 01st Oct 2020 06:40

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Launches bead-assisted mass spectrometry, or BAMS, SARS-CoV-2 virus test. "The BAMS assay uses the Affimer reagents specific to the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry, using the installed base of these instruments in hospitals," Avacta says. Adds that one thousand samples per day can be analysed by a single technician using BAMS.

Current stock price: 155.00 pence, up 11% on Wednesday.

Year-to-date change: up sharply from 17.25p

By Eric Cunha; ericcunha@alliancenews.com

Related Shares

More News

Today 11:53

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...

30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

22 Apr 2024 17:51

TRADING UPDATES: First Tin updates Tellerhauser estimates

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thur...